Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trialFrancesco Perrone, Ciro Gallo, Michelino De Laurentiis et al.|European Journal of Cancer|2019Cited by 71
Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trialFrancesco Perrone, A. De Matteis, Francesco Nuzzo et al.|Annals of Oncology|2014Cited by 68
Eribulin for metastatic breast cancer (MBC) treatment: a retrospective, multicenter study based in Campania, south Italy (Eri-001 trial)Michele Orditura, Fortunato Ciardiello, Adriano Gravina et al.|ESMO Open|2017Cited by 13
Psychometric properties of patient-reported outcomes Common Terminology Criteria for adverse events (PRO-CTCAE®) in breast cancer patients: The prospective observational multicenter VIP studyCaterina Caminiti, Francesco Perrone, Francesco Nuzzo et al.|The Breast|2024Cited by 2